Please use this identifier to cite or link to this item: https://ninho.inca.gov.br/jspui/handle/123456789/6901
Title: HPV18 Utilizes Two Alternative Branch Sites for E6*I Splicing to Produce E7 Protein
Authors: Brant, Ayslan Castro
Majerciak, Vladimir
Moreira, Miguel Angelo Martins
Zheng, Zhi-Ming
Keywords: Human papillomavirus 18
Papillomavirus Humano 18
HPV-18
Papillomavirus E7 Proteins
Proteínas E7 de Papillomavirus
Issue Date: 2019
Publisher: Virologica Sinica
Abstract: Human papillomavirus 18 (HPV18) E6 and E7 oncogenes are transcribed as a single bicistronic E6E7 pre-mRNA. The E6 ORF region in the bicistronic E6E7 pre-mRNA contains an intron. Splicing of this intron disrupts the E6 ORF integrity and produces a spliced E6*I RNA for efficient E7 translation. Here we report that the E6 intron has two overlapped branch point sequences (BPS) upstream of its 3' splice site, with an identical heptamer AACUAAC, for E6*I splicing. One heptamer has a branch site adenosine (underlined) at nt 384 and the other at nt 388. E6*I splicing efficiency correlates to the expression level of E6 and E7 proteins and depends on the selection of which branch site. In general, E6*I splicing prefers the 3'ss-proximal branch site at nt 388 over the distal branch site at nt 384. Inactivation of the nt 388 branch site was found to activate a cryptic acceptor site at nt 636 for aberrant RNA splicing. Together, these data suggest that HPV18 modulates its production ratio of E6 and E7 proteins by alternative selection of the two mapped branch sites for the E6*I splicing, which could be beneficial in its productive or oncogenic infection according to the host cell environment.
URI: http://sr-vmlxaph03:8080/jspui/handle/123456789/6901
ISSN: 1995-820X
Appears in Collections:Artigos de Periódicos da Pesquisa Experimental e Translacional

Files in This Item:
File Description SizeFormat 
HPV18 Utilizes Two Alternative Branch Sites for E6 I Splicing to Produce E7 Protein.pdf951.06 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.